
Pfizer Inc. Announces FDA Approval Of DUAVEETM (conjugated estrogens/ bazedoxifene) For The Treatment Of Moderate-To-Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause And The Prevention Of Postmenopausal Osteoporosis
DUAVEE is the first and only therapy to pair conjugated estrogens with an estrogen agonist/antagonist, also known as a selective estrogen receptor modulator (SERM) [2]
Thursday, October 3, 2013 – 4:14pm EDT
NEW YORK, N.Y., October 3 – Pfizer Inc. (NYSE: PFE), a leader in the development of treatments for menopausal symptoms, is pleased to announce that the United States Food and Drug Administration (FDA) has approved DUAVEETM (conjugated estrogens/bazedoxifene) 0.45mg / 20mg tablets, a novel therapy for women with a uterus, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis
read all http://www.pharmalive.com/fda-approves-pfizer-s-duavee
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....

Reblogged this on Med.Chem.in.Iceland.
LikeLike